Parmax Pharma EGM passes three resolutions, rejects two

Parmax Pharma Limited held an Extra Ordinary General Meeting (EGM) on May 27, 2026, to vote on the appointment and re-appointment of key directors. The meeting, chaired by Managing Director Umang Alkesh Gosalia, saw shareholders pass resolutions for the Managing Director and two Non-Executive Directors while rejecting proposals for two Independent Directors. The voting process included a remote e-voting facility conducted by Purva Sharegistry India Private Limited, which was open from May 24 to May 26, 2026, alongside ballot paper voting at the meeting.

Voting Results Summary

The company sought approval for five resolutions. While the resolutions for the Managing Director and two non-executive directors received the requisite majority, the proposals for two independent directors failed to secure the necessary approval under the Companies Act, 2013. The scrutinizer for the EGM was M/s. Samsad Alam Khan.

Passed Resolutions

Shareholders approved the re-appointment of Umang Alkesh Gosalia as Managing Director. The resolution received 100% of the valid votes cast, with 2,145,178 shares voted in favor and none against. Additionally, the appointments of Pradeep Ramniklal Gosalia and Salma Badrudin Thobhani as Non-Executive Directors were passed. The resolution for Pradeep Ramniklal Gosalia received 57.04% of the valid votes, while Salma Badrudin Thobhani's appointment secured 69.95% of the valid votes.

Resolution	Votes For	Votes Against	% For	Status
Re-appointment of Umang Alkesh Gosalia (MD)	2,145,178	0	100.00	Passed
Appointment of Pradeep Ramniklal Gosalia (NED)	1,337,664	704,800	57.04	Passed
Appointment of Salma Badrudin Thobhani (NED)	1,640,377	704,801	69.95	Passed

Rejected Resolutions

The EGM saw the rejection of two special resolutions regarding the appointment of independent directors. The proposal to appoint Ashish Atmaram Shah received 69.95% of the valid votes in favor but did not meet the higher threshold required for a special resolution. Similarly, the appointment of Anjana Paresh Shah was not passed, having received the same percentage of votes in favor. Both resolutions faced opposition from public non-institutional shareholders.

Resolution	Votes For	Votes Against	% For	Status
Appointment of Ashish Atmaram Shah (ID)	1,640,378	704,800	69.95	Not Passed
Appointment of Anjana Paresh Shah (ID)	1,640,377	704,801	69.95	Not Passed

Shareholder Participation

A total of 2,345,178 votes were polled, representing approximately 62.68% of the total outstanding shares. The promoter group cast all of its 1,152,450 shares in favor of all resolutions. Public non-institutional shareholders participated with 1,192,728 votes, showing significant opposition to the resolutions for independent directors.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+5.32%	+7.62%	+25.81%	+9.89%	-14.10%	-32.76%

Parmax Pharma Limited has rescheduled its board meeting to Tuesday, June 02, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The decision to reschedule the meeting was taken due to unavoidable reasons, as communicated to the stock exchanges.

Regulatory Compliance

The rescheduled meeting is being held pursuant to Regulation 29 of the SEBI Listing Regulations, 2015. This announcement is in continuation of a previous corporate announcement dated May 27, 2026.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code to regulate, monitor, and report trading by insiders, the trading window for dealing in the securities of Parmax Pharma Limited remains closed. The window will reopen 48 hours after the announcement of the audited financial results for the quarter and financial year ended March 31, 2026.